Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 4/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.60 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.60 |
| ▸ | HTR6 | P50406 | 3/20 | 0.50 |
| ▸ | HTR1A | P08908 | 2/20 | 0.50 |
| ▸ | HTR7 | P34969 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR5A | P47898 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.42 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4443137 | 0.81 | ALDH1A1 (0.42) | CSNK1DMAPK14MAPK11LMNA | |
| SCHEMBL1686076 | 0.78 | CSNK1D (0.47) | CSNK1DMAPK14MAPK11HTR6HTR1A | |
| SCHEMBL18404765 | 0.78 | CSNK1D (0.47) | CSNK1DMAPK14MAPK11HTR6HTR1A | |
| SCHEMBL2954143 | 0.76 | MAPK14 (0.60) | CSNK1DMAPK14MAPK11HTR6HTR1A | |
| SCHEMBL1754670 | 0.75 | MAPK14 (1.00) | CSNK1DMAPK14MAPK11HTR6HTR1A | |
| Hydrochloric Acid SCHEMBL2955401 | 0.75 | MAPK14 (0.58) | CSNK1DMAPK14MAPK11HTR6HTR1A | |
| SCHEMBL1753201 | 0.75 | MAPK14 (1.00) | CSNK1DMAPK14MAPK11HTR6HTR1A | |
| SCHEMBL2951404 | 0.74 | CKS1B (0.54) | — | |
| SCHEMBL1753176 | 0.72 | CSNK1D (0.60) | CSNK1DMAPK14MAPK11HTR6HTR1A | |
| SCHEMBL10465983 | 0.70 | ADRB1 (0.68) | CSNK1DMAPK14MAPK11HTR6HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422296-B2 | Fast-dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2016-08-23 | — | — | US | disclosed |
| US-9422296-B2 | Fast-dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2016-08-23 | — | — | US | disclosed |
| US-9422296-B2 | Fast-dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2016-08-23 | — | — | US | disclosed |
| US-20140336381-A1 | FAST-DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-13 | — | — | US | disclosed |
| US-20140336381-A1 | FAST-DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-13 | — | — | US | disclosed |
| US-20140336381-A1 | FAST-DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-13 | — | — | US | disclosed |
| US-8791120-B2 | Fast-dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-29 | — | — | US | disclosed |
| US-8791120-B2 | Fast-dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-29 | — | — | US | disclosed |
| US-8791120-B2 | Fast-dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-29 | — | — | US | disclosed |
| EP-2121630-B1 | FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-01 | — | — | EP | disclosed |
| EP-2121630-B1 | FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-01 | — | — | EP | disclosed |
| US-20100069394-A1 | FAST-DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, NV (BE) | 2010-03-18 | — | — | US | disclosed |
| US-20100069394-A1 | FAST-DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, NV (BE) | 2010-03-18 | — | — | US | disclosed |
| US-20100069394-A1 | FAST-DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, NV (BE) | 2010-03-18 | — | — | US | disclosed |
| EP-2121630-A1 | FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008098892-A1 | FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008098892-A1 | FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336381-A1 | FAST-DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | DRD2, GRIN2C, GRIN2A | CSNK1D 752/4885MAPK14 2169/4885MAPK11 1663/4885 |
| US-20100069394-A1 | FAST-DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | DRD2, GRIN2C, GRIN2A | CSNK1D 752/4885MAPK14 2169/4885MAPK11 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.